Iscover

Clopidogrel, the active ingredient in Iscover, is an antiplatelet agent presented as an oral tablet for systemic use. It inhibits platelet aggregation to reduce the risk of cardiovascular events in patients with a history of myocardial infarction, ischemic stroke, or peripheral arterial disease.

GNH USA supplies Iscover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with validated quality systems and export capabilities. The company adheres to EU GMP standards and provides regulatory documentation for seamless market entry.

Clopidogrel is an antiplatelet agent used to reduce thrombotic events in several cardiovascular conditions.

- Myocardial infarction: lowers the risk of recurrent heart attacks in patients with prior MI. - Ischemic stroke: diminishes the chance of a subsequent stroke in individuals who have experienced an ischemic event. - Peripheral arterial disease: helps prevent limb‑related ischemic complications and cardiovascular events in patients with PAD.

Clopidogrel may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bleeding gums or easy bruising - Nosebleeds (epistaxis) - Diarrhea or abdominal discomfort - Skin rash or itching

Serious or Rare Side Effects: - Severe or uncontrolled bleeding (e.g., gastrointestinal, intracranial) - Thrombotic thrombocytopenic purpura (TTP) - Anaphylactic or severe allergic reactions - Significant liver enzyme elevations - Neutropenia or other blood dyscrasias

Before initiating clopidogrel therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Assess bleeding risk: review history of gastrointestinal ulcers or recent surgery. - Monitor liver function: perform periodic hepatic enzyme tests. - Adjust in renal impairment: consider dose modification in severe renal dysfunction. - Avoid in active pathological bleeding: discontinue if major bleeding occurs. - Store at room temperature: keep in the original pack, protect from moisture and light.

Clopidogrel interacts with several drug classes that can alter its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid): - CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) may reduce activation of clopidogrel. - Concurrent strong antiplatelet agents (e.g., aspirin, ticagrelor) increase bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) such as ibuprofen can exacerbate bleeding. - Warfarin or other anticoagulants may lead to excessive hemorrhage. - Selective serotonin reuptake inhibitors (SSRIs) may potentiate bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) may lower clopidogrel effectiveness. - Certain proton pump inhibitors (e.g., pantoprazole) have modest impact on platelet inhibition. - Statins (e.g., atorvastatin) can increase plasma levels of clopidogrel's active metabolite.